Dermatology

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.

A budget impact model projects that covering delgocitinib cream for moderate to severe chronic hand eczema could save a hypothetical US health plan $87.8 million over 3 years, driven mostly by lower drug costs.

Dermatologists spend 13 hours weekly on prior authorization as health plans tout an 11% reduction in requests.

Telehealth care for atopic dermatitis matched in-person outcomes in a study, signaling a scalable option for underserved patients.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.

New evidence links oxidative stress to vitiligo autoimmunity, highlighting antioxidant plus phototherapy or JAK combinations for better repigmentation.

Everyday skincare may expose you to microplastics and plastic-linked chemicals tied to skin disease and hormone disruption; dermatologists urge safer products and packaging.

Cancer survivors face lasting skin, hair, and nail reactions; dermatology follow-up and treatments can restore appearance, improve quality of life, and monitor risks.

Photodynamic therapy expands from actinic keratosis to acne, infections, and rejuvenation—while experts urge clearer, mechanism-based guidelines.

Financial toxicity independently predicts a lower quality of life for patients with HS, with greater disease severity and biologic use driving the strain.

After vitiligo diagnosis, many patients remain untreated and switch quickly between therapies, according to new data on treatment patterns.

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population.

At-home phototherapy is more convenient than in-office care, and investigators found its one-time costs are also far less than the cost of care in a clinic.

From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access, equity, and patient outcomes.

Chronic skin diseases are increasingly being understood as systemic conditions driven by the interconnected brain-gut-skin axis.

Expert insights reveal how to spot inflammation in deeply pigmented skin and use new biologics and melasma therapies to reduce dyspigmentation.

Secukinumab becomes the only IL-17A inhibitor approved for this population and the first new mechanism in the indication in nearly a decade.

Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, supporting potential pediatric label expansion.

The mental health burden of vitiligo closely resembles atopic dermatitis but differs significantly from psoriasis, a study suggests.

Patients identified as having a Janus kinase inhibitor responder profile were much more likely to respond positively to the class of atopic dermatitis therapies.

April Armstrong, MD, MPH, discusses choosing AD therapies, JAK inhibitor safety, response measures, and emerging treatments shaping the field.

A Winter Clinical Miami poster highlights intralesional cemiplimab for early CSCC, showing rapid responses and positive safety vs surgery.

The data in these posters address a central clinical question: can a topical JAK1/JAK2 inhibitor deliver robust efficacy while maintaining a reassuring safety profile?

Transcriptomic analysis revealed that chronic hand eczema shares overlapping immune signatures with both atopic dermatitis and psoriasis.

More than 57% of patients with ACD reported moderate to severe quality-of-life impairment, with symptoms and embarrassment among the most affected areas.